[go: up one dir, main page]

PE20190633A1 - Anticuerpos anti-gm-csf y usos de los mismos - Google Patents

Anticuerpos anti-gm-csf y usos de los mismos

Info

Publication number
PE20190633A1
PE20190633A1 PE2019000664A PE2019000664A PE20190633A1 PE 20190633 A1 PE20190633 A1 PE 20190633A1 PE 2019000664 A PE2019000664 A PE 2019000664A PE 2019000664 A PE2019000664 A PE 2019000664A PE 20190633 A1 PE20190633 A1 PE 20190633A1
Authority
PE
Peru
Prior art keywords
seq
same
antibody
cdr1
cdr2
Prior art date
Application number
PE2019000664A
Other languages
English (en)
Inventor
Zhengyi Wang
Lei Fang
Bingshi Guo
Jingwu Zang
Original Assignee
I Mab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610832677.0A external-priority patent/CN107840886B/zh
Priority claimed from CN201610831525.9A external-priority patent/CN107840885B/zh
Application filed by I Mab filed Critical I Mab
Publication of PE20190633A1 publication Critical patent/PE20190633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO AISLADO O FRAGMENTO DEL MISMO, EL CUAL TIENE ESPECIFICIDAD A UNA PROTEINA GM-CSF HUMANA Y COMPRENDE UNA VH CDR1 DE SEC ID NO: 1; UNA VH CDR2 DE SEC ID NO: 2; UNA VH CDR3 DE SEC ID NO: 3; UNA VL CDR1 DE SEC ID NO: 4; UNA VL CDR2 DE SEC ID NO: 5; Y UNA VL CDR3 DE SEC ID NO: 6; EN DONDE LA REGION VARIABLE DE CADENA PESADA DE DICHO ANTICUERPO COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 14 Y LA REGION VARIABLE DE CADENA LIVIANA COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 22. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE DICHO ANTICUERPO LA CUAL ES UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, LA ENFERMEDAD DE ADDISON, ESPONDILITIS ANQUILOSANTE
PE2019000664A 2016-09-19 2017-09-18 Anticuerpos anti-gm-csf y usos de los mismos PE20190633A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610832677.0A CN107840886B (zh) 2016-09-19 2016-09-19 Gm-csf抗体及其用途
CN201610831525.9A CN107840885B (zh) 2016-09-19 2016-09-19 Gm-csf抗体及其用途

Publications (1)

Publication Number Publication Date
PE20190633A1 true PE20190633A1 (es) 2019-04-26

Family

ID=61618639

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000664A PE20190633A1 (es) 2016-09-19 2017-09-18 Anticuerpos anti-gm-csf y usos de los mismos

Country Status (25)

Country Link
US (3) US10647767B2 (es)
EP (1) EP3328887B1 (es)
JP (1) JP7256116B2 (es)
KR (3) KR102356187B1 (es)
CN (1) CN109219616B (es)
AU (1) AU2017328383B2 (es)
BR (1) BR112019005274A2 (es)
CA (1) CA3036509C (es)
CL (1) CL2019000702A1 (es)
CO (1) CO2019002550A2 (es)
DK (1) DK3328887T3 (es)
ES (1) ES2887343T3 (es)
HU (1) HUE056238T2 (es)
IL (1) IL265331B2 (es)
MX (1) MX2019003019A (es)
MY (1) MY190021A (es)
NZ (1) NZ750976A (es)
PE (1) PE20190633A1 (es)
PH (1) PH12019500434A1 (es)
PL (1) PL3328887T3 (es)
PT (1) PT3328887T (es)
SG (1) SG11201901789WA (es)
UA (1) UA126565C2 (es)
WO (1) WO2018050111A1 (es)
ZA (2) ZA201901835B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020034097A1 (en) 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
EP3827016A4 (en) * 2018-10-15 2022-05-04 Elixiron Immunotherapeutics (Hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
CN119095584A (zh) * 2022-12-01 2024-12-06 天境生物科技(杭州)有限公司 抗gm-csf抗体的液体药物配制品及其用途
WO2024140895A1 (en) * 2022-12-30 2024-07-04 I-Mab Biopharma (Hangzhou) Co., Ltd. Compositions and methods for treating macrophage activation syndrome

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
RU2447085C2 (ru) * 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
DK1981909T3 (en) * 2006-02-08 2017-01-23 Morphotek Inc Antigenic GM¸]CSF¸]peptides and antibodies against GM¸]CSF
SG176503A1 (en) * 2006-11-21 2011-12-29 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
JP2010527939A (ja) * 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド 中和抗体
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) * 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2712166C2 (ru) * 2008-12-22 2020-01-24 Де Юниверсити Оф Мельбурн Лечение боли
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2011153592A1 (en) * 2010-06-10 2011-12-15 Crc For Asthma And Airways Ltd Therapeutic molecules
AU2011331180B2 (en) * 2010-11-18 2016-07-07 Crc For Asthma & Airways Antibody with specificity for GM-CSF (II)
EP2820045B1 (en) * 2012-03-02 2018-08-22 Vaccinex, Inc. Methods for the treatment of b cell-mediated inflammatory diseases
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
RU2714919C2 (ru) * 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
CN105031630A (zh) * 2014-04-28 2015-11-11 四川大学 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法

Also Published As

Publication number Publication date
US11926662B2 (en) 2024-03-12
IL265331A (en) 2019-05-30
US20180362632A1 (en) 2018-12-20
CN109219616A (zh) 2019-01-15
ZA202005792B (en) 2021-09-29
EP3328887A4 (en) 2019-04-03
WO2018050111A1 (en) 2018-03-22
US20190002549A1 (en) 2019-01-03
AU2017328383B2 (en) 2022-10-27
MX2019003019A (es) 2019-09-19
CL2019000702A1 (es) 2019-06-21
PL3328887T3 (pl) 2021-12-27
BR112019005274A2 (pt) 2019-06-04
KR101953706B1 (ko) 2019-03-05
US10889641B2 (en) 2021-01-12
UA126565C2 (uk) 2022-11-02
JP7256116B2 (ja) 2023-04-11
KR102356187B1 (ko) 2022-02-08
US20210079085A1 (en) 2021-03-18
MY190021A (en) 2022-03-22
NZ750976A (en) 2023-01-27
KR20190035790A (ko) 2019-04-03
IL265331B1 (en) 2023-09-01
PH12019500434A1 (en) 2019-05-20
KR20180039742A (ko) 2018-04-18
CA3036509A1 (en) 2018-03-22
EP3328887B1 (en) 2021-08-18
ZA201901835B (en) 2021-09-29
SG11201901789WA (en) 2019-03-28
CN109219616B (zh) 2022-10-21
US10647767B2 (en) 2020-05-12
PT3328887T (pt) 2021-10-19
HUE056238T2 (hu) 2022-02-28
IL265331B2 (en) 2024-01-01
AU2017328383A1 (en) 2019-03-14
CA3036509C (en) 2022-10-25
ES2887343T3 (es) 2021-12-22
KR20210007041A (ko) 2021-01-19
JP2019534850A (ja) 2019-12-05
CO2019002550A2 (es) 2019-05-21
EP3328887A1 (en) 2018-06-06
DK3328887T3 (da) 2021-09-20

Similar Documents

Publication Publication Date Title
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
PE20180499A1 (es) Anticuerpos de union a tau
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
AR109715A1 (es) Anticuerpos anti-cd27
CL2018003583A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos.
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20190261A1 (es) Anticuerpos que reconocen tau
PE20191102A1 (es) Anticuerpos anti-pd-1 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20180926A1 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20210377A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA202091747A1 (ru) Составы антитела b7-h4